Active, Not Recruiting
An Observational Study of Nivolumab in Participants With Advanced Kidney Cancer - CA209-9GY
Actualizada:
26 julio, 2023
|
ClinicalTrials.gov
Géneros
Rango de edad
Active, Not Recruiting
Inclusion Criteria: - Adult patients with the diagnosis of advanced RCC (histologically or cytologically) whose physician has already decided to initiate a treatment with nivolumab as second or third line therapy for the first time for the treatment of RCC, according to the label approved in France Exclusion Criteria: - Patients with a primary diagnosis of a cancer other than advanced RCC within the past five years, ie, a cancer other than RCC that requires systemic or other treatment - Patients previously treated with anti-PD1, anti-PDL1 or anti-CTLA4 therapy - Patients currently included in an interventional clinical trial for their advanced or RCC. Patients who have completed their participation in an interventional trial; or who are not receiving study drug anymore and who are only followed-up for OS can be enrolled Other protocol defined inclusion/exclusion criteria could apply